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Aim. To study a series of new acridine derivatives containing two basic fragments able to bind to quadruplex 
DNA at C-4 and C-9 positions as potential telomerase inhibitors. Methods. TRAP assay was used to determine 
the activity of compounds in vitro. Results. A number of acridines inhibiting the enzyme at micromolar con-
centrations were found, with IC50 = 2.6 µM for the most active compound. Conclusions. The introduction of 
a highly basic N,N-dimethylaminoalkyl group at the C-9 position of the acridine core results in a strong in-
crease of biological activity of compounds, and a 5-methyl substituent further enhances it.
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Introduction
Telomerase is a unique reverse transcriptase synthe-
sizing the telomeres using its own RNA component 
as a template and single-stranded telomeric DNA as 
a primer [1]. This enzyme is responsible for main-
taining the telomere length and re-synthesizes the 
telomeric sequences partially lost upon each cellular 
division. Telomerase is active in a majority of tumor 
cells, which results in their immortalization. 
Increased telomerase activity was detected in 85–
90 % of human tumors [2]. In contrast, it is inactive 
in normal somatic cells. So telomerase inhibitors 
have a significant potential as anticancer drugs [2, 3]. 
Guanine-rich telomeric DNA sequences can fold 
into specific four-stranded structures called G-quad ru-
plexes (G4) formed by the stacks of guanine quartets 
linked by non-canonical systems of hydrogen bonds 
[4-6]. Compounds able to specifically bind and stabi-
lize G4 structures were found to inhibit telomerase and 
demonstrated antitumor activity. A va riety of com-
pounds, mostly containing a large heteroaromatic core, 
were shown to be G4-stabilizing ligands [4, 6, 7]. 
A number of known telomerase inhibitors are 
based on acridine scaffold. Most of them contain 
pairs of basic substituents, e.g. at C-3 and C-6 or C-4 
and C-5 positions of the ring, and quite often an aro-
matic fragment at C-9 [4, 6–11]. In this work we 
have studied a series of novel 4,9-di and 4,5,9-tri-
substituted acridines as potential telomerase inhibi-
tors. Their biological testing was performed using 
the modification of classic in vitro TRAP (Telomeric 
Repeat Amplification Protocol) assay [12]. 
Materials and Methods
Acridone carboxamides 1, 2 were obtained as previ-
ously described [13]. Acridine derivatives with ali-
phatic basic 9-substituents were prepared from these 
compounds or their 5-methyl-substituted analogues 
(synthetic details will be reported in a separate paper). 
3-([3-Cholamidopropyl]-dimethylammonium)-1-
propanesulfonate (CHAPS), ethyleneglycol-bis-O-
(β-aminoethyl)-N,N’-tetraacetic acid (EGTA) and 
SYBR Green I were obtained from Sigma (USA), 
Taq-DNA-polymerase and deoxynucleoside triphos-
phates from Fermentas (Lithuania). 
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Telomerase was extracted from exponentially 
growing MCF-7 tumor cells by lysing in a CHAPS/
EGTA-based buffer [14].
TRAP analysis was performed according to 
TRAPeze protocol [TRAPeze® Telomerase Detec-
tion Kit. Chemicon International, Temecula, CA, 
USA, 2005. 39 p.] with deoxyoligonucleotide pri-
mers 5´-GTGCCCTTACCCTTACCCTTACCCTAA 
(CXext) [15] and 5´-AATCCGTCGAGCAGAGTT 
(TS) from Eurogentec (Belgium). Inhibitors were 
tested in a concentration range from 40 to 0.625 µM 
using a serial 2-fold dilution. After the telomerase 
extension reaction the tested compounds were re-
moved from the mixture by phenol/chloroform ex-
traction followed by ethanol precipitation. PCR-
amplified DNA products were analyzed by gel elec-
trophoresis. 20 µL sample was mixed with 2 µL of 
loading buffer (5x TBE buffer, 20 % sucrose, 0.2 % 
bromophenol blue) and loaded onto a standard 12 % 
non-denaturing polyacrylamide gel (19:1) prepared 
in 0.5x TBE. Electrophoresis was run for 0.5 h at 
160 V and then for 0.5 h at 300 V. Gel was stained 
with 1x SYBR Green I for 30 min at room tempera-
ture. DNA bands were visualized on a ChemiDoc 
imager (Bio-Rad, USA), and images were processed 
with TotallLab v2.01 software (Nonlinear Dyna-
mics, UK). 
Inhibition activity was determined by comparing 
the amount of DNA produced in the test assay with 
that in a control reaction with no inhibitor added. For 
quantitative analysis, optical densities of the sets of 
DNA product bands on corresponding lanes of the 
gel were integrated. IC50 values (compound concen-
trations required for achieving 50 % inhibition of 
enzymatic activity) were obtained from the concen-
tration-activity plots. At least three independent ex-
periments were performed for each compound.
Results and Discussion
We have recently found that acridone derivatives 
containing pyridyl groups at 4-carboxamide frag-
ment inhibit telomerase at 100 µM concentration. 
Molecular modeling suggested the introduction of 
additional phosphate-binding group in these com-
pounds to improve their G4 binding and thus inhibi-
tion activity [16]. A series of new acridine deriva-
tives with two aliphatic and aromatic basic frag-
ments were synthesized. The structures of potential 
inhibitors (Table) were designed taking into account 
that strongly basic group like N,N-dimethylami no-
al kyl introduced at C-9 position is easily protonated 
in water and thus could interact with G4 phosphate 
ani ons enhancing the ligand binding. In addition to 
phosphate binding, the basic pyridyl function at 
4-carboxamide was expected to form hydrophobic 
bonds with G4 DNA bases further increasing the li-
gand affinity. 
The level of telomerase inhibition was determined 
in TRAP assay. In this 2-step method [12], telome-
rase enzymatic reaction is followed by PCR amplifi-
cation of its DNA products and analysis of the result-
ing reaction mixture by gel electrophoresis. Tumor 
cell lysate is used as the source of telomerase. We 
have employed TRAPeze protocol from Chemicon 
[TRAPeze® Telomerase Detection Kit. Chemicon 
International, Temecula, CA, USA, 2005. 39 p.], a 
well-established modification of the original method 
[12]. The inhibitors were removed from the reaction 
mixture before the PCR step to exclude their possi-
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Fig. 1. TRAP analysis of the effect of acridines on telomerase 
activity. Lanes 1–3 – compound 5 (20, 10 and 5 µM); lanes 4–5 – 
compound 6 (10 and 5 µM); lanes 6–7 – compound 8 (2.5 and 
1.25 µM); lanes 8–10 – compound 7 (2.5, 1.25 and 0.625 µM); 
C – control reaction. EP – elongation products.
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ble effect on Taq-DNA-polymerase. Alternative re-
verse PCR primer CXext developed to minimize 
analysis artifacts [15] was used instead of the stan-
dard CX.
The compounds were tested in a concentration 
range 40–0.625 µM (Fig. 1). The activity plots 
built by calculating the yield of enzymatic reac-
tion products as a function of drug concentration 
allowed determining the IC50 values of inhibitors 
(Table). 
The test results confirmed the idea of structure de-
sign to be correct. 9-Acridone derivatives 1–2 with 
o- and m-pyridyl fragments were relatively inactive 
as telomerase inhibitors. However, the activity of all 
9-substituted analogues bearing strongly basic func-
tions sharply increased. The inhibition data indicated 
a higher activity of the compounds with N,N-di me-
thylaminopropyl residue (5, 6) as compared to their 
analogues containing a shorter Me2NCH2CH2 group 
(3, 4). As expected, electron-donating 5-me thyl sub-
stituent significantly enhanced the biological activity 
(compare the IC50 values of compounds 7 and 5, 8 
and 6), perhaps due to increasing the electronic den-
sity on acridine core which resulted in its more effi-
cient π-π stacking with G4. 
Conclusions
4,9- and 4,5,9-substiuted acridines containing two 
basic DNA-binding moieties efficiently inhibit telo-
me rase in vitro at low micromolar concentrations. 
Trisubstituted derivative 7 with IC50 = 2.6 µM is the 
most active inhibitor. The key structural feature de-
termining the activity of compounds is a presence of 
highly basic N,N-dimethylaminoalkyl group at C-9 
position. Further optimization would allow the de-
velopment of more potent acridine-based telo merase 
inhibitors. 
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Інгібування теломерази новими ди- та тризаміщеними 
похідними акридину
В. В. Негруцька, І. В. Сараєва, В. Г. Костіна, 
І. В. Алексєєва, Н. А. Лисенко, І. Я. Дубей 
Мета. Дослідити серію нових похідних акридину, що містять у 
положеннях С-4 і С-9 два основні фрагменти, здатні зв’я зу ва ти-
ся з квадруплексною ДНК, як потенційних інгібіторів теломера-
зи. Методи. Для визначення активності сполук in vitro викорис-
тано метод TRAP. Результати. Виявлено ряд акридинів, що інгі-
бують фермент у низьких мікромолярних концентраціях, для 
найактивнішого з яких ІС50 = 2.6 мкМ. Висновки. При введенні 
високоосновної N,N-диметиламіноалкільної групи в положення 
С-9 акридинового ядра біологічна активність сполук різко зрос-
тає, а 5-метильний замісник додатково збільшує її. 
К л юч ов і  с л ов а: інгібітори теломерази, акридини, квадру-
плексна ДНК, TRAP 
Ингибирование теломеразы новыми ди- и 
тризамещенными производными акридина
В. В. Негруцкая, И. В. Сараева, В. Г. Костина, 
И. В. Алексеева, Н. А. Лысенко, И. Я. Дубей 
Цель. Изучить серию новых производных акридина, содержа-
щих в положениях С-4 и С-9 два основных фрагмента, способ-
ных связываться с квадруплексной ДНК, как потенциальных 
ингибиторов теломеразы. Методы. Для определения активности 
веществ in vitro использован метод TRAP. Результаты. 
Обнаружен ряд акридинов, ингибирующих фермент в низких 
микромолярных концентрациях, для самого активного из кото-
рых ІС50 = 2.6 мкM. Выводы. При введении высокоосновной 
N,N-диметиламиноадкильной группы в положении С-9 акриди-
нового ядра биологическая активность соединений резко возрас-
тает, а 5-метильный заместитель дополнительно увеличивает ее.
К л юч е в ы е  с л ов а: ингибиторы теломеразы, акридины, 
квадруплексная ДНК, TRAP
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